Group 1 - Crystal Holdings (02228) announced a strategic collaboration between its wholly-owned subsidiary Ailux Shanghai and Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The collaboration allows Eli Lilly to utilize Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis to create innovative and effective antibody molecules [1] - The collaboration includes upfront and milestone payments totaling several tens of millions of dollars, with a potential total value of up to $345 million, including development, regulatory, and commercial milestone payments [1] Group 2 - Ailux Shanghai is an indirect wholly-owned subsidiary of Ailux Holdings Limited, which is a wholly-owned subsidiary of Crystal Holdings [2] - Ailux serves as Crystal's exclusive biopharmaceutical innovation platform, developing advanced biotherapies through AI-driven solutions [2] - Ailux combines proprietary computational models with cutting-edge wet lab capabilities to tackle traditionally undruggable targets and design biologics with innovative drug potential, supported by a global team of over 100 people [2]
晶泰控股子公司AILUX宣布与礼来战略合作赋能(AI驱动)双特异性抗体开发